A randomized, open-label phase II non-inferiority study of niraparib maintenance after 3 versus 6 cycles of platinum-based chemotherapy in patients with completely debulked advanced HRD-positive high-grade ovarian cancer in first-line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62).